{"nctId":"NCT03262935","briefTitle":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","startDateStruct":{"date":"2017-12-15","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer"],"count":437,"armGroups":[{"label":"(vic-)trastuzumab duocarmazine","type":"EXPERIMENTAL","interventionNames":["Drug: (vic-)trastuzumab duocarmazine"]},{"label":"Physician's choice","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Physician's choice"]}],"interventions":[{"name":"(vic-)trastuzumab duocarmazine","otherNames":["SYD985","Trastuzumab vc-seco-DUBA"]},{"name":"Physician's choice","otherNames":["Lapatinib (Lap)","Capecitabine (Cap)","Trastuzumab (T)","Vinorelbine (Vino)","Eribulin (Eri)"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Female patients with histologically-confirmed, unresectable locally advanced or metastatic breast cancer;\n* Patients should have had either progression during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease or progression during or after (ado-)trastuzumab emtansine treatment for locally advanced or metastatic disease;\n* HER2-positive tumor status;\n* Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2;\n* Estimated life expectancy \\> 12 weeks at randomization;\n* Adequate organ function and blood cell counts.\n\nMain Exclusion Criteria:\n\n* Current or previous use of a prohibited medication as listed in the protocol;\n* History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;\n* History of keratitis;\n* Severe, uncontrolled systemic disease at screening;\n* Left Ventricular Ejection Fraction (LVEF) \\< 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;\n* Cardiac troponin value above the Upper Limit of Normal (ULN);\n* History of clinically significant cardiovascular disease;\n* Untreated brain metastases, symptomatic brain metastases, brain metastases requiring steroids to manage symptoms, or treatment for brain metastases within 8 weeks prior to randomization;\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression-free survival is defined as the time from the date of randomization to the date of first documented disease progression by central assessment according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurred earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is defined as the time from date of randomization to death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"Objective Response Rate is defined as the proportion of patients with a centrally assessed best overall response of complete response or partial response according to RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator Assessed Progression Free Survival","description":"Progression-free survival is defined as the time from the date of randomization to the date of first documented disease progression by investigator assessment according to RECIST v1.1 or death due to any cause, whichever occurred earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcomes for Health Related Quality of Life","description":"Change in the global health status/Quality of Life (QoL) scale score of the European Organization for Research and Treatment for Cancer (EORTC) Quality of Life Questionnaire C30 from baseline (cycle 1). The raw score (1 to 7) has been transformed to a score ranging from 0 to 100. A higher score means a better outcome: hence a positive change from baseline means an improvement in global health status/Quality of Life and a negative change from baseline means a worsening of global health status/Quality of Life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"-3.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.88","spread":null},{"groupId":"OG001","value":"-2.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.48","spread":null},{"groupId":"OG001","value":"-9.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":null},{"groupId":"OG001","value":"-5.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.65","spread":null},{"groupId":"OG001","value":"-6.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.14","spread":null},{"groupId":"OG001","value":"-11.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.70","spread":null},{"groupId":"OG001","value":"-10.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.40","spread":null},{"groupId":"OG001","value":"-12.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.90","spread":null},{"groupId":"OG001","value":"-14.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.31","spread":null},{"groupId":"OG001","value":"-0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.45","spread":null},{"groupId":"OG001","value":"1.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.68","spread":null},{"groupId":"OG001","value":"-11.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.30","spread":null},{"groupId":"OG001","value":"-7.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.76","spread":null},{"groupId":"OG001","value":"-11.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"-5.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-6.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-7.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-15.73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":288},"commonTop":["Fatigue","Keratitis","Nausea","Conjunctivitis","Diarrhoea"]}}}